Thabor Therapeutics, a company developing a treatment for patients living with chronic mucosal inflammatory diseases, has secured €2 million ($2.09m) in funding from the French public investment bank Bpifrance, as part of its Deeptech Plan.
This funding will enable Thabor to accelerate its R&D programs and to build upon the very encouraging results achieved since the company was founded in June 2021; for the industrial development of its monoclonal antibodies and an IND (Investigational New Drug) application.
The funding from Bpifrance is another step towards the series A round planned for Q4, 2022. Thabor also intends to use the money for further staff recruitment to strengthen its team.
